logo

INO

Inovio Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

INO fundamentals

Inovio Pharmaceuticals (INO) released its earnings on Nov 10, 2025: revenue was 0 (YoY -100.00%), missed estimates; EPS was -0.87 (YoY +2.25%), missed estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-0.87
+2.25%
Report date
Nov 10, 2025
INO Earnings Call Summary for Q3,2025
  • BLA Milestone Achieved: INO-3107 BLA submission completed; FDA file acceptance expected by year-end with potential mid-2026 approval.
  • Cost Efficiency: 22% YoY reduction in operating expenses; cash runway extended to Q2 2026.
  • Differentiated RRP Treatment: INO-3107 avoids MRD surgeries during dosing, showing 78% reduction in surgeries vs. baseline.
  • Innovative Pipeline: DMAb technology achieves durable antibody production; DPROT preclinical data for Factor VIII shows promise for hemophilia.
EPS
Revenue

Revenue & Expenses

Key Indicators

Inovio Pharmaceuticals (INO) key financial stats and ratios, covering profitability, financial health, and leverage.
Inovio Pharmaceuticals (INO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Inovio Pharmaceuticals (INO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Inovio Pharmaceuticals (INO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Inovio Pharmaceuticals (INO) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Inovio Pharmaceuticals (INO) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield